multimeric-001
Vaccineexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00877448)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- multimeric-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03058692 | Phase 2 | Jul 6, 2017 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02691130 | Phase 2 | Nov 1, 2015 | BiondVax Pharmaceuticals, St Istvan St Laszlo hospital |
| NCT01419925 | Phase 2 | Aug 1, 2011 | BiondVax Pharmaceuticals, Tel Aviv University |
| NCT01146119 | Phase 2 | Jul 1, 2010 | BiondVax Pharmaceuticals, Hebrew University, Tel Aviv University |
| NCT01010737 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | BiondVax Pharmaceuticals, Tel Aviv University |
| NCT00877448 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2009 | BiondVax Pharmaceuticals, Tel Aviv University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BiondVax Pharmaceuticals | For profit | 5 | 5 | 1 | 2009 |
| Tel Aviv University | Academic/Hospital | 4 | 0 | 1 | 2009 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2017 |
| St Istvan St Laszlo hospital | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1